OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
20
Results
Show all
Save search
Copy query
Show results for
Unknown
(15)
Genomics
(5)
Organisms
Homo sapiens
(5)
Repository
EGA
(5)
Release Date
2022
(3)
2020
(2)
2014
(2)
2025
(1)
2024
(1)
2023
(1)
2018
(1)
2017
(1)
2015
(1)
2010
(1)
2009
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer.
Not available
S-EPMC4650662
|
biostudies-literature
Cite
Molecular mimicry between tumor associated antigens and microbiota-derived epitopes.
Not available
S-EPMC9281086
|
biostudies-literature
Cite
SARS-CoV-2 RNA polymerase as target for antiviral therapy.
Not available
S-EPMC7200052
|
biostudies-literature
Cite
Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy.
Not available
S-EPMC6977281
|
biostudies-literature
Cite
Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients.
Not available
S-EPMC6194606
|
biostudies-literature
Cite
Evolutionary divergence of chloroplast FAD synthetase proteins.
Not available
S-EPMC2972280
|
biostudies-literature
Cite
Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients.
Not available
S-EPMC9927035
|
biostudies-literature
Cite
The HMGA1 Pseudogene 7 Induces miR-483 and miR-675 Upregulation by Activating Egr1 through a ceRNA Mechanism.
Not available
S-EPMC5704243
|
biostudies-literature
Cite
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review.
Not available
S-EPMC9735901
|
biostudies-literature
Cite
Cancer-associated CD43 glycoforms as target of immunotherapy.
Not available
S-EPMC3954431
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets